Cargando…

Prevalence of hepatic steatosis and associated factors in Iranian patients with chronic hepatitis C

Background: Hepatic steatosis is commonly observed in patients with chronic hepatitis C (CHC). Many studies indicate a relationship between steatosis and fibrosis progression. The aim of this study was to analyze the prevalence of hepatic steatosis and related factors in Iranian CHC patients. Method...

Descripción completa

Detalles Bibliográficos
Autores principales: Poortahmasebi, Vahdat, Emami Aleagha, Mohammad Sajad, Amiri, Mehdi, Qorbani, Mostafa, Farahmand, Mohammad, Asayesh, Hamid, Alavian, Seyed Moayed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Iran University of Medical Sciences 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4898852/
https://www.ncbi.nlm.nih.gov/pubmed/27390692
_version_ 1782436403248889856
author Poortahmasebi, Vahdat
Emami Aleagha, Mohammad Sajad
Amiri, Mehdi
Qorbani, Mostafa
Farahmand, Mohammad
Asayesh, Hamid
Alavian, Seyed Moayed
author_facet Poortahmasebi, Vahdat
Emami Aleagha, Mohammad Sajad
Amiri, Mehdi
Qorbani, Mostafa
Farahmand, Mohammad
Asayesh, Hamid
Alavian, Seyed Moayed
author_sort Poortahmasebi, Vahdat
collection PubMed
description Background: Hepatic steatosis is commonly observed in patients with chronic hepatitis C (CHC). Many studies indicate a relationship between steatosis and fibrosis progression. The aim of this study was to analyze the prevalence of hepatic steatosis and related factors in Iranian CHC patients. Methods: One hundred and fifteen consecutive patients with CHC were enrolled which were treatment- naïve. The patients were divided into groups with and without steatosis according to the result of liver biopsy (58.3% and 41.7%, respectively). Demographic, histological, biochemical and virological factors were examined and compared in all patients. Results: In terms of host factors, body mass index (BMI), triglyceride, fasting blood glucose (FBG), necroinflammatory activity and severity in fibrosis of CHC patients with steatosis was significantly higher than the patients without steatosis. Of viral factors, HCV viral load was not significantly altered in patients with steatosis. Moreover, HCV genotypes did not meet such association. Using multivariate regression analysis, parameters of BMI values, FBG level and stage of fibrosis were independently associated with steatosis. Conclusion: Our data indicate that CHC patients are more susceptible to development of hepatic steatosis. Based on our results, grade of steatosis appears to be associated with hepatic fibrosis progression rate in CHC patients.
format Online
Article
Text
id pubmed-4898852
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Iran University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-48988522016-07-07 Prevalence of hepatic steatosis and associated factors in Iranian patients with chronic hepatitis C Poortahmasebi, Vahdat Emami Aleagha, Mohammad Sajad Amiri, Mehdi Qorbani, Mostafa Farahmand, Mohammad Asayesh, Hamid Alavian, Seyed Moayed Med J Islam Repub Iran Original Article Background: Hepatic steatosis is commonly observed in patients with chronic hepatitis C (CHC). Many studies indicate a relationship between steatosis and fibrosis progression. The aim of this study was to analyze the prevalence of hepatic steatosis and related factors in Iranian CHC patients. Methods: One hundred and fifteen consecutive patients with CHC were enrolled which were treatment- naïve. The patients were divided into groups with and without steatosis according to the result of liver biopsy (58.3% and 41.7%, respectively). Demographic, histological, biochemical and virological factors were examined and compared in all patients. Results: In terms of host factors, body mass index (BMI), triglyceride, fasting blood glucose (FBG), necroinflammatory activity and severity in fibrosis of CHC patients with steatosis was significantly higher than the patients without steatosis. Of viral factors, HCV viral load was not significantly altered in patients with steatosis. Moreover, HCV genotypes did not meet such association. Using multivariate regression analysis, parameters of BMI values, FBG level and stage of fibrosis were independently associated with steatosis. Conclusion: Our data indicate that CHC patients are more susceptible to development of hepatic steatosis. Based on our results, grade of steatosis appears to be associated with hepatic fibrosis progression rate in CHC patients. Iran University of Medical Sciences 2016-02-07 /pmc/articles/PMC4898852/ /pubmed/27390692 Text en © 2016 Iran University of Medical Sciences http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0), which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
spellingShingle Original Article
Poortahmasebi, Vahdat
Emami Aleagha, Mohammad Sajad
Amiri, Mehdi
Qorbani, Mostafa
Farahmand, Mohammad
Asayesh, Hamid
Alavian, Seyed Moayed
Prevalence of hepatic steatosis and associated factors in Iranian patients with chronic hepatitis C
title Prevalence of hepatic steatosis and associated factors in Iranian patients with chronic hepatitis C
title_full Prevalence of hepatic steatosis and associated factors in Iranian patients with chronic hepatitis C
title_fullStr Prevalence of hepatic steatosis and associated factors in Iranian patients with chronic hepatitis C
title_full_unstemmed Prevalence of hepatic steatosis and associated factors in Iranian patients with chronic hepatitis C
title_short Prevalence of hepatic steatosis and associated factors in Iranian patients with chronic hepatitis C
title_sort prevalence of hepatic steatosis and associated factors in iranian patients with chronic hepatitis c
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4898852/
https://www.ncbi.nlm.nih.gov/pubmed/27390692
work_keys_str_mv AT poortahmasebivahdat prevalenceofhepaticsteatosisandassociatedfactorsiniranianpatientswithchronichepatitisc
AT emamialeaghamohammadsajad prevalenceofhepaticsteatosisandassociatedfactorsiniranianpatientswithchronichepatitisc
AT amirimehdi prevalenceofhepaticsteatosisandassociatedfactorsiniranianpatientswithchronichepatitisc
AT qorbanimostafa prevalenceofhepaticsteatosisandassociatedfactorsiniranianpatientswithchronichepatitisc
AT farahmandmohammad prevalenceofhepaticsteatosisandassociatedfactorsiniranianpatientswithchronichepatitisc
AT asayeshhamid prevalenceofhepaticsteatosisandassociatedfactorsiniranianpatientswithchronichepatitisc
AT alavianseyedmoayed prevalenceofhepaticsteatosisandassociatedfactorsiniranianpatientswithchronichepatitisc